(Credit-Canva)
Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!
The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.
"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.
The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.
While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.
And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.
Credits: AI GENERATED
In a serious caution to the public, Dr Uma Kumar, Head of Rheumatology at AIIMS New Delhi, has warned against using AI chatbots such as ChatGPT for medical self-diagnosis. As reported by Hindustan Times, she issued the warning while speaking to the media after a recent case at the institute exposed the risks of acting on automated health advice.
The concern followed an incident in which a patient developed severe internal bleeding after treating back pain based on suggestions generated by an AI chatbot. The patient consumed non-steroidal anti-inflammatory drugs without consulting a doctor or undergoing basic medical tests.
According to doctors at AIIMS, the patient relied on an AI tool to manage persistent back pain instead of seeking clinical care. The chatbot recommended commonly used painkillers, which the patient purchased and took independently.
As Hindustan Times noted, the AI system had no access to the patient’s medical history or their risk of stomach and intestinal complications. What appeared to be a routine solution resulted in a life-threatening episode of internal bleeding.
Doctors say this reflects a growing pattern, where quick online answers are replacing medical evaluation, even for drugs that are widely available over the counter.
Dr Kumar explained that medical diagnosis follows a structured process known as diagnosis by exclusion. Doctors rule out possible causes through examinations, laboratory tests, imaging, and patient history before deciding on treatment.
An AI model, however, works by identifying patterns in data. It cannot examine a patient, detect physical warning signs, or judge whether a symptom points to a deeper problem. In this case, proper investigations would likely have revealed a high risk of bleeding, a step that was entirely bypassed.
Medical experts are increasingly concerned about what are often called AI hallucinations, where chatbots present information with confidence despite gaps or inaccuracies.
While platforms such as ChatGPT include disclaimers, their tone can appear authoritative, particularly to someone in pain. As highlighted by Hindustan Times, the recommendation to use NSAIDs was not unusual in general practice, but for this patient, it proved dangerous.
Without a doctor to check for contraindications or underlying conditions, even a common suggestion can lead to serious harm.
The incident has renewed debate over how AI platforms should handle health-related queries. AIIMS doctors are urging the public to treat online tools as sources of general information rather than personal treatment guides.
Experts believe AI can assist healthcare in limited roles, such as research support or administrative tasks, but should never replace professional diagnosis or supervision.
There are also calls for stronger public awareness and clearer regulation to prevent similar incidents. Doctors continue to stress that medical judgment, built on examination and evidence, cannot be replaced by algorithms.
Credits: AI GENERATED
The Delhi High Court has turned down a Japanese company’s attempt to secure a patent for a cancer detection technique that relies on nematodes, or roundworms, ruling that it falls under diagnostic processes that cannot be patented under Indian law, regardless of how novel or non-invasive it may be.
Hirotsu Bio Science approached the High Court after India’s Controller of Designs and Patents rejected its patent application in August 2023, stating that the invention did not meet the criteria laid out in the Patents Act, 1970. In a detailed 25-page judgment delivered on Saturday, Justice Tejas Karia reaffirmed Section 3(i) of the Act, which clearly bars the patenting of diagnostic methods.
The nematode-based cancer detection method is a research-stage technique that uses microscopic roundworms, known as nematodes, to detect the presence of cancer. These organisms possess a highly developed sense of smell, allowing them to pick up on specific chemical cues released by cancer cells in bodily samples such as urine, breath, or tissue, as per Science Direct.
Laboratory experiments have shown that certain nematodes tend to move towards samples taken from individuals with cancer while avoiding those from healthy people. The underlying idea is that cancer changes the body’s chemical profile, creating odour patterns that these worms can detect, sometimes even at an early stage.
Scientists have looked at this approach as a potentially affordable and non-invasive screening option. However, it remains a concept under study and has not yet been accepted as a reliable medical test or used in routine clinical care.
At the centre of the case was a patent application titled “Cancer detection method using the sense of smell of nematode.” Nematodes, often referred to as roundworms, are among the most widespread life forms on the planet and can be found in environments ranging from soil to living organisms.
The Japanese company aimed to patent a technology based on the biological response of Caenorhabditis elegans, a species of nematode recognised for its advanced olfactory abilities.
The firm explained that its invention relies on the chemotaxis of these worms, meaning their tendency to move towards or away from certain scents, which would serve as a biological signal for the presence of cancer.
According to the company, the nematodes showed avoidance behaviour when exposed to urine from healthy individuals, while being drawn towards urine samples from cancer patients. It claimed the method demonstrated complete accuracy during testing and could detect several cancers, including gastric, colorectal, and pancreatic cancers, even at very early stages.
The main legal question was whether the method qualified as a non-patentable “diagnostic process” under Section 3(i) of the Patents Act, 1970. This provision excludes from patent protection any process related to medicinal, surgical, curative, preventive, diagnostic, or therapeutic treatment of humans.
Hirotsu Bio Science Inc challenged the rejection by the Controller of Designs and Patents in the High Court, arguing that their invention should be seen as a “detection” method rather than a “diagnostic” one. The company maintained that the process was carried out entirely in a laboratory setting, using samples such as urine or tissue, and did not involve any direct medical procedure or clinical decision-making on the human body.
Credit: Canva
Health officials have issued a recall for the Live It Up Super Greens supplement powder after 45 people across 21 states were found suffering from salmonella across the US.
The Food and Drug Administration and Centers for Disease Control and Prevention issued an official recall on January 14 for the Live it Up Original and Wild Berry Super Greens dietary supplement powder flavors.
The affected products with expiration dates from August 2026 and January 2028 have been affected by this recall and include:
Authorities has advised consumers to not eat, sell or serve the affected Live it Up-brand products and to contact the company for returns.
Additionally, officials are asking people to wash items and surfaces that may have touched the recalled super greens supplement powders using hot soapy water or a dishwasher.
Of the 45 illnesses, 12 resulted in hospitalizations, according to the FDA. No deaths linked to the recall have been reported.
Apart from this, other symptoms include:
Most people develop symptoms within 8 to 72 hours after exposure while most healthy people recover within a few days to a week without specific treatment. However, in some cases, diarrhea can cause severe dehydration and requires prompt medical attention.
While anyone can contract salmonella, children younger than five, elderly and people with weakened immune systems are more likely to develop severe infections.
Life-threatening complications may develop if the infection spreads beyond the intestines to other organs. The risk of getting salmonella infection is higher with travel to countries without clean drinking water and proper sewage disposal.
While most people do not require medical attention for salmonella infection, those at high risk may need a health care provider if the infection lasts more than a few days, is associated with high fever or bloody stools and appears to be causing dehydration, with signs such as such as urinating less than usual, dark-colored urine as well as having a dry mouth and tongue.
© 2024 Bennett, Coleman & Company Limited